Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Moderate to Severe Palmoplantar Psoriasis
NCT00585650Phase 2Completed
- Sponsor
- University of California, Irvine
- Start
- May 2007
- Primary completion
- May 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etanercept in palmoplantar psoriasis (2 arms), sponsored by University of California, Irvine. Primary endpoint: The Number of Subjects Who Achieve a 50% Reduction in the Palmoplantar Psoriasis Severity Index at 12 Weeks. Started May 2007; status: completed.
02
Drugs
etanercept
03
Conditions
palmoplantar psoriasis
Beyond the preview
Go deeper on NCT00585650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585650.